Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

Fig. 3

HAQ trajectories of patient groups pRLDA (remission-low) and pMDA (moderate) and subgroups plMDA (lower-moderate) and phMDA (higher-moderate). RA, rheumatoid arthritis; HAQ, functionality measured by Health Assessment Questionnaire; pRLDA, patients with persistent remission or low disease activity; pMDA, patients with persistent moderate disease activity; plMDA, patients with persistent lower-moderate disease activity; phMDA, patients with persistent higher-moderate disease activity

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us